In clinical trials that assessed the safety and efficacy of cangrelor during percutaneous coronary intervention (PCI), cangrelor was administered as a 30-μg/kg bolus followed by a 4-μg/kg/min infusion for at least 2 hours or the duration of the PCI, whichever was longer.
The Medicines Company has reported results of CHAMPION PHOENIX, a 11,145 patient Phase III randomized, double-blind clinical trial comparing the...
A pooled analysis of three Phase III clinical trials of cangrelor, from The Medicines Company, confirm the results of the...
The Medicines Company announced the approval of Kengreal (cangrelor) by the FDA as an adjunctive therapy to percutaneous coronary intervention...
The Medicines Company has announced results for its pivotal Phase III clinical trial of cangrelor, which is in development to...
Kengrexal, co-administered with acetylsalicylic acid (ASA), is indicated for the reduction of thrombotic cardiovascular events in adult patients with coronary artery disease undergoing percutaneous coronary intervention (PCI) who have not received an oral P2Y12 inhibitor prior to the PCI procedure and in whom oral therapy with P2Y12 inhibitors is not feasible or desirable.
New data demonstrates that intravenous use of cangrelor, from AstraZeneca, was effective at maintaining platelet inhibition in patients on thienopyridines...
The FDA has accepted the new drug application (NDA) for The Medicines Company intravenous antiplatelet cangrelor as a treatment in...
Antiplatelet therapy with a P2Y12 inhibitor is a key component of treatment for patients with acute coronary syndromes undergoing percutaneous coronary intervention.